Inclusion Criteria:

- Age ≥ 18 years.

- Histopathologically confirmed diagnosis of a metastatic non-hematologic malignancy.

- ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2

- Adequate renal function [creatinine ≤ 1.5x ULN (upper limit of normal)]

- Adequate hepatic function (total bilirubin ≤ 1.5x ULN (upper limit of normal) for the
institution; AST [aspartate transaminase] and ALT [alanine transaminase] ≤ 3x ULN, or
≤ 5x ULN if due to liver involvement by tumor).

- Adequate bone marrow function (hemoglobin ≥ 9.0 g/dL; unsupported platelets ≥ 100 x10
9 cells/L; absolute neutrophil count ≥ 1.5x10 9 cells/L

- Corrected QT interval (QTc) < 470 ms

- Subjects must have at least one tumor lesion that is suitable for repeat biopsy, and
must agree to two tumor biopsies (pre- and post- treatment).

- Willing and able to participate in the trial and comply with all trial requirements.

Exclusion Criteria:

- Gastrointestinal (GI) condition which could interfere with the swallowing or
absorption of study medication.

- Uncontrolled or severe concurrent medical condition (including uncontrolled brain
metastases).

- History of upper gastrointestinal bleeding, ulceration, or perforation within 12
months.

- Known history of stroke or cerebrovascular accident within 6 months.

- Subjects being actively treated for a secondary malignancy.